


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the July 2011 NCCN Trends™ Survey, which focused on Hematologic Malignancies. This survey was sent to U.S. and International users of NCCN.org.

DEMOGRAPHICS

Distribution of Respondent Types (n = 1,396)†




†Note: Percentages may not total 100 because of rounding


© National Comprehensive Cancer Network, Inc. 2011, All Rights Reserved. For Personal Use Only.

This report may not be reproduced or distributed beyond personal use in any form without the express written permission of NCCN.


Q1. Do you treat or care for patients with Hematologic Malignancies?
(n = 1,396)



Q2. Within the past year, how many patients with Chronic Myelogenous Leukemia (CML) have you managed? (n = 748)




By Geography†




†Note: Percentages may not total 100 because of rounding

Q2. Within the past year, how many patients with Chronic Myelogenous Leukemia (CML) have you managed? (n = 748)

By Practice Size†




By Practice Setting†



†Note: Percentages may not total 100 because of rounding


Q2. Within the past year, how many patients with Chronic Myelogenous Leukemia (CML) have you managed? (n = 748)

By Specialty†



†Note: Percentages may not total 100 because of rounding


Q3. Of the CML patients you managed last year, what percentage developed resistance to their second or more TKI therapy (either imatinib, dasatinib, or nilotinib) within the past year?† (n = 728)




†Note: Percentages may not total 100 because of rounding

Q3. Of the CML patients you managed last year, what percentage developed resistance to their second or more TKI therapy (either imatinib, dasatinib, or nilotinib) within the past year? (n = 728)

By Geography†




By Practice Size†




†Note: Percentages may not total 100 because of rounding

Q3. Of the CML patients you managed last year, what percentage developed resistance to their second or more TKI therapy (either imatinib, dasatinib, or nilotinib) within the past year? (n = 728)

By Practice Setting†




By Specialty†



†Note: Percentages may not total 100 because of rounding

Q4. Please rate your level of familiarity for each of the following products that are currently being evaluated as therapies for patients with CML:


- Not at all familiar (never heard of drug)
- Somewhat familiar (drug name familiar, not able to recall data)
- Moderately familiar (know drug name and able to recall some data)
- Very familiar (can discuss drug and data in-depth)



Q4. Please rate your level of familiarity for each of the following products that are currently being evaluated as therapies for patients with CML:

By Geography†

- Not at all familiar (never heard of drug)
- Somewhat familiar (drug name familiar, not able to recall data)
- Moderately familiar (know drug name and able to recall some data)
- Very familiar (can discuss drug and data in-depth)




†Note: Percentages may not total 100 because of rounding

Q4. Please rate your level of familiarity for each of the following products that are currently being evaluated as therapies for patients with CML:

By Practice Size †


- Not at all familiar (never heard of drug)
- Somewhat familiar (drug name familiar, not able to recall data)
- Moderately familiar (know drug name and able to recall some data)
- Very familiar (can discuss drug and data in-depth)



†Note: Percentages may not total 100 because of rounding

Q4. Please rate your level of familiarity for each of the following products that are currently being evaluated as therapies for patients with CML:

By Practice Setting†




†Note: Percentages may not total 100 because of rounding

Q4. Please rate your level of familiarity for each of the following products that are currently being evaluated as therapies for patients with CML:


By Specialty†

- Not at all familiar (never heard of drug)
- Somewhat familiar (drug name familiar, not able to recall data)
- Moderately familiar (know drug name and able to recall some data)
- Very familiar (can discuss drug and data in-depth)




†Note: Percentages may not total 100 because of rounding

Q5. In the past three (3) months, for which of the following regimens have you substituted bendamustine or a bendamustine containing regimen due to a lack of supply? Please check all that apply. (n = 596)




Q5. In the past three (3) months, for which of the following regimens have you substituted bendamustine or a bendamustine containing regimen due to a lack of supply? Please check all that apply. (n = 596)

By Geography




Q5. In the past three (3) months, for which of the following regimens have you substituted bendamustine or a bendamustine containing regimen due to a lack of supply? Please check all that apply. (n = 596)

By Practice Size




Q5. In the past three (3) months, for which of the following regimens have you substituted bendamustine or a bendamustine containing regimen due to a lack of supply? Please check all that apply. (n = 596)

By Practice Setting




Q5. In the past three (3) months, for which of the following regimens have you substituted bendamustine or a bendamustine containing regimen due to a lack of supply? Please check all that apply. (n = 596)

By Specialty



Q6. How many unique patients did you personally prescribe the following therapies in the following clinical situation over the past three (3) months?†

Indolent Non-Hodgkin's Lymphoma, induction therapy (n = 486)




†Note: Percentages may not total 100 because of rounding

Q6. How many unique patients did you personally prescribe the following therapies in the following clinical situation over the past three (3) months?

Indolent Non-Hodgkin's Lymphoma, induction therapy (n = 486)

By Geography†




†Note: Percentages may not total 100 because of rounding

Q6. How many unique patients did you personally prescribe the following therapies in the following clinical situation over the past three (3) months?

Indolent Non-Hodgkin's Lymphoma, induction therapy (n = 486)

By Practice Size†




†Note: Percentages may not total 100 because of rounding

Q6. How many unique patients did you personally prescribe the following therapies in the following clinical situation over the past three (3) months?

Indolent Non-Hodgkin's Lymphoma, induction therapy (n = 486)

By Practice Setting†




†Note: Percentages may not total 100 because of rounding

Q6. How many unique patients did you personally prescribe the following therapies in the following clinical situation over the past three (3) months?

Indolent Non-Hodgkin's Lymphoma, induction therapy (n = 486)

Specialty†



†Note: Percentages may not total 100 because of rounding

NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.com - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.